POINT Biopharma Global Inc.
PNTNASDAQHealthcare
$12.50
+$0.02(+0.16%)
Market Cap$1.3B
P/E Ratio—
52W High$14.35
52W Low$6.57
POINT Biopharma Global Inc. (PNT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PNT · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 13, 2023EPS Actual
-$0.23
Est. -$0.30 · +23.3%
Revenue
$0.00B
Est. $0.00B · +43.8%
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 13, 2023
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
PNT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 13, 2023 | -$0.30 | -$0.23 | +23.3% | $0.00B | $0.00B | +43.8% |
| ▲ Q3 FY2023 | Aug 14, 2023 | -$0.29 | -$0.24 | +17.2% | $0.00B | $0.00B | +417.6% |
| ▲ Q2 FY2023 | May 15, 2023 | -$0.32 | -$0.16 | +50.0% | $0.01B | $0.23B | -95.8% |
| ▲ Q1 FY2023 | Mar 27, 2023 | -$0.26 | $1.53 | +688.5% | $0.23B | $0.03B | +771.5% |
| ▲ Q4 FY2022 | Nov 14, 2022 | -$0.28 | -$0.26 | +7.1% | — | — | — |
| ▼ Q3 FY2022 | Aug 12, 2022 | -$0.22 | -$0.27 | -22.7% | — | — | — |
| ▲ Q2 FY2022 | May 13, 2022 | -$0.20 | -$0.18 | +10.0% | — | — | — |
| ▲ Q1 FY2022 | Mar 25, 2022 | -$0.20 | -$0.16 | +20.0% | — | — | — |
Q4 FY2023
Nov 13, 2023Beat
EPS Actual
-$0.23
EPS Est.
-$0.30
EPS Surpr.
+23.3%
Revenue
$0.00B
Q3 FY2023
Aug 14, 2023Beat
EPS Actual
-$0.24
EPS Est.
-$0.29
EPS Surpr.
+17.2%
Revenue
$0.00B
Q2 FY2023
May 15, 2023Beat
EPS Actual
-$0.16
EPS Est.
-$0.32
EPS Surpr.
+50.0%
Revenue
$0.01B
Q1 FY2023
Mar 27, 2023Beat
EPS Actual
$1.53
EPS Est.
-$0.26
EPS Surpr.
+688.5%
Revenue
$0.23B
Q4 FY2022
Nov 14, 2022Beat
EPS Actual
-$0.26
EPS Est.
-$0.28
EPS Surpr.
+7.1%
Revenue
—
Q3 FY2022
Aug 12, 2022Miss
EPS Actual
-$0.27
EPS Est.
-$0.22
EPS Surpr.
-22.7%
Revenue
—
Q2 FY2022
May 13, 2022Beat
EPS Actual
-$0.18
EPS Est.
-$0.20
EPS Surpr.
+10.0%
Revenue
—
Q1 FY2022
Mar 25, 2022Beat
EPS Actual
-$0.16
EPS Est.
-$0.20
EPS Surpr.
+20.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.68 | $1.54 | $0.68 | 1 |
| Q2 FY2024 | $1.46 | $1.34 | $0.59 | 1 |
| Q1 FY2024 | $1.72 | $1.58 | $0.70 | 4 |
| Q4 FY2023 | $-0.37 | $-0.37 | $-0.15 | 9 |
| Q3 FY2023 | $-0.36 | $-0.32 | $-0.19 | 10 |
| Q2 FY2023 | $-0.32 | $-0.29 | $-0.13 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 5 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 13, 2023 | +23.3% | $13.12 | $13.37 | +1.91% |
| ▲ Q3 FY2023 | Aug 14, 2023 | +17.2% | $8.99 | $8.63 | -4.00% |
| ▲ Q2 FY2023 | May 15, 2023 | +50.0% | $9.56 | $10.50 | +9.83% |
| ▲ Q1 FY2023 | Mar 27, 2023 | +688.5% | $6.81 | $7.00 | +2.79% |
| ▲ Q4 FY2022 | Nov 14, 2022 | +7.1% | $9.14 | $5.72 | -37.42% |
| ▼ Q3 FY2022 | Aug 12, 2022 | -22.7% | $8.11 | $8.83 | +8.88% |
| ▲ Q2 FY2022 | May 13, 2022 | +10.0% | $5.62 | $5.79 | +3.02% |
| ▲ Q1 FY2022 | Mar 25, 2022 | +20.0% | $6.65 | $6.76 | +1.65% |
Q4 FY2023+1.91%
Report Date
Nov 13, 2023
EPS Beat/Miss
+23.3%
Price Before
$13.12
Price After
$13.37
Q3 FY2023-4.00%
Report Date
Aug 14, 2023
EPS Beat/Miss
+17.2%
Price Before
$8.99
Price After
$8.63
Q2 FY2023+9.83%
Report Date
May 15, 2023
EPS Beat/Miss
+50.0%
Price Before
$9.56
Price After
$10.50
Q1 FY2023+2.79%
Report Date
Mar 27, 2023
EPS Beat/Miss
+688.5%
Price Before
$6.81
Price After
$7.00
Q4 FY2022-37.42%
Report Date
Nov 14, 2022
EPS Beat/Miss
+7.1%
Price Before
$9.14
Price After
$5.72
Q3 FY2022+8.88%
Report Date
Aug 12, 2022
EPS Beat/Miss
-22.7%
Price Before
$8.11
Price After
$8.83
Q2 FY2022+3.02%
Report Date
May 13, 2022
EPS Beat/Miss
+10.0%
Price Before
$5.62
Price After
$5.79
Q1 FY2022+1.65%
Report Date
Mar 25, 2022
EPS Beat/Miss
+20.0%
Price Before
$6.65
Price After
$6.76
Avg Beat Reaction-3.17%
Avg Miss Reaction+8.88%
Beat Rate7 / 8 quarters
Largest Move-37.42% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PNT ends December
POINT Biopharma Global Inc. (PNT) most recently reported earnings on November 13, 2023 for Q4 FY2023, posting EPS of $-0.23 — beating the analyst consensus of $-0.30 by +23.3%. PNT has beaten EPS estimates for 5 consecutive quarters. The next PNT earnings date is expected around September 1, 2026.
Each quarter, investors track PNT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PNT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PNT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PNT earnings · 5 questionsPOINT Biopharma Global Inc.'s next earnings report is expected around September 1, 2026. PNT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PNT historically reports after market close (AMC).
PNT earnings datewhen is PNT earningsPNT next earnings datewhen does PNT report earningsPNT earnings calendar
▸ Source: FMP · POINT Biopharma Global Inc. SEC filings · US GAAP · POINT Biopharma Global Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026